Neurodegenerative Diseases
Neurodegenerative diseases (NDs) are a heterogeneous group of complex diseases characterized by neuronal loss and progressive degeneration of different areas of the nervous system. NDs represent a significant health problem worldwide, with an increasing incidence rate. Although the exact pathogenesi...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_98956 | ||
| 005 | 20230405 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20230405s2023 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-7074-7 | ||
| 020 | |a 9783036570754 | ||
| 020 | |a 9783036570747 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-7074-7 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a GP |2 bicssc | |
| 072 | 7 | |a PS |2 bicssc | |
| 072 | 7 | |a PSB |2 bicssc | |
| 100 | 1 | |a Ciaccio, Marcello |4 edt | |
| 700 | 1 | |a Agnello, Luisa |4 edt | |
| 700 | 1 | |a Ciaccio, Marcello |4 oth | |
| 700 | 1 | |a Agnello, Luisa |4 oth | |
| 245 | 1 | 0 | |a Neurodegenerative Diseases |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
| 300 | |a 1 electronic resource (262 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Neurodegenerative diseases (NDs) are a heterogeneous group of complex diseases characterized by neuronal loss and progressive degeneration of different areas of the nervous system. NDs represent a significant health problem worldwide, with an increasing incidence rate. Although the exact pathogenesis of NDs remains unclear, a complex interaction among genetic, epigenetic, and environmental factors has been proposed. To date, no effective therapeutics have been developed to slow, halt, or prevent any NDs. Thus, information on the molecular mechanisms underlying the pathogenesis of NDs is strongly sought after. This Special Issue collected papers discussing advances in the field of NDs. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Research & information: general |2 bicssc | |
| 650 | 7 | |a Biology, life sciences |2 bicssc | |
| 650 | 7 | |a Biochemistry |2 bicssc | |
| 653 | |a menopause | ||
| 653 | |a estrogen | ||
| 653 | |a neurodegenerative disease | ||
| 653 | |a Alzheimer's disease | ||
| 653 | |a IGF-1 | ||
| 653 | |a NMDAR | ||
| 653 | |a Parkinson's disease | ||
| 653 | |a neurodegeneration | ||
| 653 | |a genetics | ||
| 653 | |a non-coding RNAs | ||
| 653 | |a microbiome | ||
| 653 | |a mitochondria | ||
| 653 | |a epigenetics | ||
| 653 | |a biomarkers | ||
| 653 | |a precision medicine | ||
| 653 | |a EAE | ||
| 653 | |a glutamate receptor antagonist | ||
| 653 | |a excitotoxicity | ||
| 653 | |a oxidative stress | ||
| 653 | |a -SH groups | ||
| 653 | |a superoxide dismutase | ||
| 653 | |a circulating microRNA | ||
| 653 | |a relapsing-remitting multiple sclerosis | ||
| 653 | |a secondary progressive multiple sclerosis | ||
| 653 | |a biomarker | ||
| 653 | |a neuroinflammation | ||
| 653 | |a Rab1 | ||
| 653 | |a GTPases | ||
| 653 | |a secretory pathway | ||
| 653 | |a Golgi fragmentation | ||
| 653 | |a autophagy | ||
| 653 | |a α-synuclein | ||
| 653 | |a LRRK2 | ||
| 653 | |a mercury | ||
| 653 | |a central nervous system | ||
| 653 | |a proteomic | ||
| 653 | |a motor functions | ||
| 653 | |a rotenone | ||
| 653 | |a dopamine | ||
| 653 | |a dopamine-D3-receptor | ||
| 653 | |a buspirone | ||
| 653 | |a chicoric acid | ||
| 653 | |a peripheral immune system | ||
| 653 | |a spleen | ||
| 653 | |a gut | ||
| 653 | |a 6-hydroxydopamine | ||
| 653 | |a apoptosis | ||
| 653 | |a mitochondrial membrane potential | ||
| 653 | |a neurodegenerative diseases | ||
| 653 | |a cell culture techniques | ||
| 653 | |a neurodegenerative disorders | ||
| 653 | |a neuroprotective effect | ||
| 653 | |a biological products | ||
| 653 | |a striatum | ||
| 653 | |a caspase-3 | ||
| 653 | |a spiny projection neurons | ||
| 653 | |a dendritic spines | ||
| 653 | |a long-term depression | ||
| 653 | |a Q-VD-OPh | ||
| 653 | |a mice | ||
| 653 | |a blood-brain barrier | ||
| 653 | |a extracellular matrix | ||
| 653 | |a fibronectin | ||
| 653 | |a liposomes | ||
| 653 | |a multiple sclerosis | ||
| 653 | |a nanomedicine | ||
| 653 | |a oligodendrocytes | ||
| 653 | |a PLGA | ||
| 653 | |a remyelination | ||
| 653 | |a therapeutic targets | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/7009 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/98956 |7 0 |z DOAB: description of the publication |